` VTGN (VistaGen Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

V
VTGN
vs
S&P 500

Over the past 12 months, VTGN has underperformed S&P 500, delivering a return of -5% compared to the S&P 500's +15% growth.

Stocks Performance
VTGN vs S&P 500

Loading
VTGN
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
VTGN vs S&P 500

Loading
VTGN
S&P 500
Difference
www.alphaspread.com

Performance By Year
VTGN vs S&P 500

Loading
VTGN
S&P 500
Add Stock

Competitors Performance
VistaGen Therapeutics Inc vs Peers

S&P 500
VTGN
ABBV
AMGN
GILD
VRTX
Add Stock

VistaGen Therapeutics Inc
Glance View

Market Cap
96.3m USD
Industry
Biotechnology

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system (CNS) disorders. The company is headquartered in South San Francisco, California and currently employs 31 full-time employees. The company went IPO on 2010-10-18. The firm is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). The firm's pipeline includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that is preparing for Phase III clinical trial for social anxiety disorder (SAD), PH10, a neuroactive nasal spray that is planning for Phase 2b development as a stand-alone treatment for depressive disorder (MDD), and AV-101 which the Company is developing for the treatment of depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy. In addition, the Company has developed a human pluripotent stem cell (hPSC) technology platform, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs).

VTGN Intrinsic Value
0.69 USD
Overvaluation 80%
Intrinsic Value
Price
V
Back to Top